## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tesamorelin-statins`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tesamorelin-statins/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-statins/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tesamorelin-statins/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tesamorelin-statins/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tesamorelin-statins/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tesamorelin-statins/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tesamorelin-statins` v2 · content_hash `9e84f5da5b491841…` · thread_head genesis · 30 DIVs
- **thesis (c1):** Tesamorelin reduced visceral adipose tissue by 15.2% versus 5% increase with placebo in a 26-week randomized trial.
  - c2 [human/active] Triglycerides decreased by 50 mg/dL with tesamorelin versus 9 mg/dL increase with placebo over 26 weeks.
  - c3 [human/active] Co-administration of tesamorelin with simvastatin produced an 8% decrease in simvastatin AUC with minimal CYP3A impact.
  - c4 [human/active] VAT and triglyceride reductions were sustained over 52 weeks in an open-label extension without worsening glucose parameters.
  - c5 [anecdotal/active] Public discussion of the tesamorelin-statin combination on Reddit and X is sparse and lacks detailed outcome reports.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tesamorelin-statins/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tesamorelin-statins/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tesamorelin-statins`
- **title:** Tesamorelin and Statins: Evidence on Visceral Fat, Lipids, and Repair Pathways
- **url:** https://miscsubjects.com/a/tesamorelin-statins
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:26.614Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have Statins

Statins primarily manage blood lipids by inhibiting HMG-CoA reductase in the liver. This reduces circulating cholesterol and lowers cardiovascular risk in many people. For readers exploring this cross, the relevant layers include potential muscle effects in a subset of users, debated impacts on glucose handling or cognition in sensitive individuals, and ongoing visceral fat accumulation that statins do not directly target. 

If your profile includes excess visceral adipose tissue, that tissue releases inflammatory signals and free fatty acids that can worsen metabolic stress. Statins address one pathway (hepatic cholesterol synthesis) but leave visceral fat reduction to diet, exercise, or other interventions. The condition persists when breakdown signals (inflammation from VAT) outrun repair processes in adipose and muscle tissue.

## Why Tesamorelin might help you

1. You are reading about **Statins** — what breaks down matters before any compound name.
2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.

Tesamorelin stimulates the growth hormone axis. In human trials this led to measurable reductions in visceral adipose tissue. If visceral fat contributes to your lipid or inflammatory burden while on statins, lowering that depot may reduce the metabolic load that statins alone do not touch. The pathway is indirect: less VAT often correlates with improved triglyceride and total cholesterol readings in the same studies.

If muscle recovery or lean mass maintenance matters alongside statin use, the same GH-axis stimulation preserved or slightly increased lean body mass in trial participants without worsening glucose control. This differs from simple suppression of cholesterol production.

## Why Statins matters for you

**Drug:** Statins

**What it does:** Lipid management; debated cognitive/muscle side effects in subset.

**Therefore for you:** Statins reduce mechanical and inflammatory load on arteries by lowering circulating lipids. This supports cardiovascular stability but does not directly repair or reduce visceral fat stores. Any muscle side effects in sensitive users represent a potential trade-off against tissue repair pathways, making compounds that act on the GH axis a separate layer to consider rather than a replacement.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **Tesamorelin** → GH axis / visceral fat

Tesamorelin addresses the visceral fat layer that statins leave untouched. Statins handle hepatic cholesterol output. Together they operate on distinct but overlapping metabolic compartments: one reduces production signals in the liver, the other reduces the adipose source of free fatty acids and inflammation. The studies that measured lipids during tesamorelin use already included participants on lipid-lowering therapy, showing additive directional changes in triglycerides without major pharmacokinetic interference with simvastatin.

## What the evidence actually shows

Human trials (multiple Phase 2/3, NEJM 2007, extension to 52 weeks, PLOS One 2017) consistently report 15–18% reductions in visceral adipose tissue measured by CT or MRI after 26–52 weeks of tesamorelin. Triglycerides fell 37–51 mg/dL and total cholesterol-to-HDL ratio improved modestly. These changes occurred in HIV patients with lipodystrophy, many already on antiretrovirals and some on statins. LDL and non-HDL cholesterol also declined in one 12-week diabetes cohort. No clinically meaningful worsening of glucose parameters appeared across trials.

A pharmacokinetic study found only an 8% drop in simvastatin AUC when co-administered with tesamorelin, described as minimal impact on CYP3A activity. Statin use did not blunt the VAT reduction in at least one liver-fat trial.

Preclinical data are limited and not required for the observed human lipid shifts. Animal models of GHRH analogs show fat redistribution but add little to the human lipid endpoint data.

Anecdotal reports on public forums remain sparse for the specific tesamorelin-statin pairing; most discussion centers on tesamorelin for VAT alone.

## What scientists say

Researchers note that VAT reduction with tesamorelin correlates with lipid improvements and reduced liver fat in HIV cohorts. They emphasize that effects on HDL are small or slightly negative over longer periods and that tesamorelin is not positioned as primary lipid-lowering therapy. The mechanism is tied to increased pulsatile GH and IGF-1 rather than direct HMG-CoA inhibition.

## What people say on Reddit

Public threads mention statins and peptides in separate contexts (lipid management versus body-composition agents) but contain almost no direct user reports pairing tesamorelin with ongoing statin therapy. Discussions focus on individual lipid responses or peptide access rather than combined use.

## What people say on X

Conversations on X about tesamorelin center on visceral-fat outcomes in approved populations. Mentions alongside statins are rare and mostly note concurrent use without reported conflicts.

## What we do not know

Long-term outcomes beyond 52 weeks in non-HIV populations on statins are absent. No large trials test tesamorelin specifically as an adjunct for statin-related muscle symptoms or for primary prevention lipid targets. Effects on cognitive endpoints or exact muscle repair markers in statin users remain unstudied.

## Safety and limits

Human trials report injection-site reactions, arthralgia, and myalgia as common adverse events. Glucose parameters stayed stable, but monitoring is standard in product labeling. The evidence base is strongest for VAT reduction in HIV lipodystrophy and weaker for broader metabolic use or statin co-administration. All claims above derive from published human data; individual responses vary.

## Claims (5)

- **c1** [human w=0.8] Tesamorelin reduced visceral adipose tissue by 15.2% versus 5% increase with placebo in a 26-week randomized trial.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] Triglycerides decreased by 50 mg/dL with tesamorelin versus 9 mg/dL increase with placebo over 26 weeks.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c4** [human w=0.8] VAT and triglyceride reductions were sustained over 52 weeks in an open-label extension without worsening glucose parameters.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c3** [human w=0.8] Co-administration of tesamorelin with simvastatin produced an 8% decrease in simvastatin AUC with minimal CYP3A impact.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c5** [anecdotal w=0.3] Public discussion of the tesamorelin-statin combination on Reddit and X is sparse and lacks detailed outcome reports.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/tesamorelin-statins/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `29e53d47f711885f`

### s1 · pubmed · ok
- title: Metabolic effects of a growth hormone-releasing factor in patients with HIV
- url: https://pubmed.ncbi.nlm.nih.gov/18057338/
- summary: NEJM 2007 randomized trial: 15.2% VAT reduction, triglyceride drop of 50 mg/dL.
- quote: Daily tesamorelin for 26 weeks decreased visceral fat and improved lipid profiles
- claim_ids: c1, c2
- hash: `af156be8b7588397`

### s2 · pubmed · ok
- title: Impact of Tesamorelin on CYP3A activity
- url: https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/cpdd.27
- summary: Pharmacokinetic study showing minimal interaction.
- quote: multiple 2 mg doses of tesamorelin administered with simvastatin resulted in an 8% decrease in simvastatin AUC
- claim_ids: c3
- hash: `ac7b3f166f4721d1`

### s3 · pubmed · ok
- title: Long-term safety and effects of tesamorelin
- url: https://pubmed.ncbi.nlm.nih.gov/18690162/
- summary: 52-week extension data.
- quote: sustained decreases in VAT and triglycerides over 52 weeks without aggravating glucose
- claim_ids: c4
- hash: `905340b4f3cde84d`

### s4 · reddit · ok
- title: statins insulin and inflammation
- url: https://www.reddit.com/r/PeterAttia/comments/1u6ol0c/statins_insulin_and_inflammation/
- summary: Isolated unrelated mention; no paired outcome reports found.
- quote: Tesamorelin for fat loss and build muscle.
- claim_ids: c5
- hash: `29e53d47f711885f`

## Provenance (2 model passes)
- chain valid: yes · head: `c2e13e8d7f60d375`

- write · grok/grok-4.3 · 2026-06-29T23:12 · hash `3514d234e9f3`
- voxel_divide · owner · 2026-07-17T02:42 · hash `c2e13e8d7f60`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tesamorelin-statins/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tesamorelin-statins/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tesamorelin-statins","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tesamorelin-statins|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tesamorelin-statins|tier|assertion`
- **iMessage ask:** `tesamorelin-statins|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tesamorelin-statins`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-statins/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tesamorelin-statins/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*